Lin, Chenchu
Blessing, Alicia M.
Pulliam, Thomas L.
Shi, Yan
Wilkenfeld, Sandi R.
Han, Jenny J.
Murray, Mollianne M.
Pham, Alexander H.
Duong, Kevin
Brun, Sonja N.
Shaw, Reuben J.
Ittmann, Michael M. http://orcid.org/0000-0003-4802-0978
Frigo, Daniel E. http://orcid.org/0000-0002-0713-471X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA184208, P30CA0166772)
American Cancer Society (RSG-16-084-01-TBE)
U.S. Department of Health & Human Services | National Institutes of Health
UT | University of Texas MD Anderson Cancer Center (Internal Research Grant, Moon Shots Program)
University of Houston (Robert Hazelwood Graduate Fellowship for Cancer Research)
CFP Foundation
Article History
Received: 26 June 2020
Revised: 18 December 2020
Accepted: 14 January 2021
First Online: 2 February 2021
Compliance with ethical standards
:
: DEF has received research funding from GTx, Inc and has a familial relationship with Hummingbird Bioscience, MAIA Biotechnology, Alms Therapeutics, Hinova Pharmaceuticals and Barricade Therapeutics. AMB is currently employed by and has stock in Clovis Oncology. The other authors report no potential conflicts of interest.